| DASISION | ENESTnd | |||
---|---|---|---|---|---|
Median follow-up (months) | 18 | NR | |||
Minimum follow-up (months) | 16 | 24 | |||
 | Dasatinib 100 mg QD | Imatinib 400 mg QD | Nilotinib 300 mg BID | Nilotinib 400 mg BID | Imatinib 400 mg QD |
 | (N = 259) | (N = 260) | (N = 282) | (N = 281) | (N = 283) |
Confirmed complete cytogenetic response by 18 mo (%) | 78 | 70 | NR | NR | NR |
Major molecular response at any time (%) | 57 | 41 | 71 | 67 | 44 |
Complete molecular response at any time (%) | 13 | 7 | 26 | 21 | 10 |
Overall survival (%) | 96.0 | 97.9 | 97.4 | 97.8 | 96.4 |
Progression-free survival (%) | 94.9 | 93.7 | 98 | 97.7 | 95.2 |
Discontinued treatment (%) | 19 | 20 | 26 | 22 | 33 |